Update on glucocorticoid action and resistance

Donald Y M Leung, John W Bloom

Research output: Contribution to journalArticle

331 Citations (Scopus)

Abstract

Glucocorticoids (GCs) are the most common group of medications used in the treatment of allergic and autoimmune disorders. They produce potent anti-inflammatory effects by inducing or repressing the expression of target genes. Although most patients with allergic diseases and autoimmune disorders respond to GC therapy, a small subset of patients demonstrate persistent tissue inflammation despite treatment with high doses of GCs. This condition results from an interaction between susceptibility genes, the host's environment, and immunologic factors. The treatment of these patients requires a systematic approach to rule out underlying conditions that lead to steroid resistance or treatment failure, as well as the use of alternative strategies to inhibit tissue inflammation.

Original languageEnglish (US)
Pages (from-to)3-22
Number of pages20
JournalJournal of Allergy and Clinical Immunology
Volume111
Issue number1
DOIs
StatePublished - Jan 1 2003

Fingerprint

Glucocorticoids
Inflammation
Immunologic Factors
Therapeutics
Treatment Failure
Autoimmune Diseases
Anti-Inflammatory Agents
Steroids
Gene Expression
Glucocorticoid Receptor Deficiency
Genes

Keywords

  • Asthma
  • Glucocorticoid
  • Steroid-resistant asthma
  • T cells

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Update on glucocorticoid action and resistance. / Leung, Donald Y M; Bloom, John W.

In: Journal of Allergy and Clinical Immunology, Vol. 111, No. 1, 01.01.2003, p. 3-22.

Research output: Contribution to journalArticle

@article{b8280c36e3414de6800db1c67f5054fb,
title = "Update on glucocorticoid action and resistance",
abstract = "Glucocorticoids (GCs) are the most common group of medications used in the treatment of allergic and autoimmune disorders. They produce potent anti-inflammatory effects by inducing or repressing the expression of target genes. Although most patients with allergic diseases and autoimmune disorders respond to GC therapy, a small subset of patients demonstrate persistent tissue inflammation despite treatment with high doses of GCs. This condition results from an interaction between susceptibility genes, the host's environment, and immunologic factors. The treatment of these patients requires a systematic approach to rule out underlying conditions that lead to steroid resistance or treatment failure, as well as the use of alternative strategies to inhibit tissue inflammation.",
keywords = "Asthma, Glucocorticoid, Steroid-resistant asthma, T cells",
author = "Leung, {Donald Y M} and Bloom, {John W}",
year = "2003",
month = "1",
day = "1",
doi = "10.1067/mai.2003.97",
language = "English (US)",
volume = "111",
pages = "3--22",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Update on glucocorticoid action and resistance

AU - Leung, Donald Y M

AU - Bloom, John W

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Glucocorticoids (GCs) are the most common group of medications used in the treatment of allergic and autoimmune disorders. They produce potent anti-inflammatory effects by inducing or repressing the expression of target genes. Although most patients with allergic diseases and autoimmune disorders respond to GC therapy, a small subset of patients demonstrate persistent tissue inflammation despite treatment with high doses of GCs. This condition results from an interaction between susceptibility genes, the host's environment, and immunologic factors. The treatment of these patients requires a systematic approach to rule out underlying conditions that lead to steroid resistance or treatment failure, as well as the use of alternative strategies to inhibit tissue inflammation.

AB - Glucocorticoids (GCs) are the most common group of medications used in the treatment of allergic and autoimmune disorders. They produce potent anti-inflammatory effects by inducing or repressing the expression of target genes. Although most patients with allergic diseases and autoimmune disorders respond to GC therapy, a small subset of patients demonstrate persistent tissue inflammation despite treatment with high doses of GCs. This condition results from an interaction between susceptibility genes, the host's environment, and immunologic factors. The treatment of these patients requires a systematic approach to rule out underlying conditions that lead to steroid resistance or treatment failure, as well as the use of alternative strategies to inhibit tissue inflammation.

KW - Asthma

KW - Glucocorticoid

KW - Steroid-resistant asthma

KW - T cells

UR - http://www.scopus.com/inward/record.url?scp=0037248247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037248247&partnerID=8YFLogxK

U2 - 10.1067/mai.2003.97

DO - 10.1067/mai.2003.97

M3 - Article

VL - 111

SP - 3

EP - 22

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 1

ER -